Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 5/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733934 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19GSK3BALDH1A1 | |
| SCHEMBL22108984 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19GSK3BALDH1A1 | |
| SCHEMBL9963202 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19GSK3BALDH1A1 | |
| SCHEMBL20083791 | 0.82 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19GSK3BALDH1A1 | |
| SCHEMBL1727253 | 0.79 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19USP7ALDH1A1 | |
| SCHEMBL11983398 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19USP7ALDH1A1 | |
| SCHEMBL1698523 | 0.74 | TDP1 (0.40) | MAPK13MAPK12MAPK11MAPK14DYRK1A | |
| SCHEMBL31010484 | 0.71 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL762378 | 0.70 | — | — | |
| SCHEMBL9963196 | 0.69 | ALDH1A1 (0.43) | CYP3A4DYRK1ABMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| US-20230382864-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382864-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11685719-B2 | Pyridinone MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685719-B2 | Pyridinone MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP3A4 94/4885CYP2C9 37/4885CYP2C19 41/4885 |
| US-20230382864-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | ENPP2, PLP2, PDXK | CYP3A4 2251/4885CYP2C9 2754/4885CYP2C19 1723/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP3A4 120/4885CYP2C9 51/4885CYP2C19 75/4885 |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | CYP3A4 1176/4885CYP2C9 4241/4885CYP2C19 3687/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | CYP3A4 1526/4885CYP2C9 2201/4885CYP2C19 3318/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | CYP3A4 1426/4885CYP2C9 842/4885CYP2C19 905/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | CYP3A4 1493/4885CYP2C9 974/4885CYP2C19 1128/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP3A4 94/4885CYP2C9 37/4885CYP2C19 41/4885 |
| US-11685719-B2 | Pyridinone MK2 inhibitors and uses thereof | ENPP2, PLP2, PDXK | CYP3A4 2251/4885CYP2C9 2754/4885CYP2C19 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.